NSE:KREBSBIO
KREBS BIOCHEMICALS & IND
Healthcare › Pharmaceuticals & Biotechnology
₹56.25
at close · 21 Sept 2026
Latest filings
- Trading window closed for Q2 FY27 results at Krebs Biochemicals · Compliance
- Newspaper notice published for 34th AGM on 29 September 2026 · Compliance
- 34th AGM on Sep 29, 2026; seeks nod for Rs 120 Cr Ipca Labs related party deals · Board & Shareholder Meetings
- Annual Report FY26 filed; AGM set for 29 September 2026 · Results
- Notice of 34th AGM on 29 September 2026 via video conferencing · Compliance
- Newspaper publication of Q1 FY27 unaudited financial results · Compliance
- Q1 FY27 results: revenue up 27 percent, loss narrows to Rs 2.48 cr · Results
- Board Meeting on Aug 6 2026 to Consider Q1 FY27 Results · Board & Shareholder Meetings
- Reg 74(5) Depository Certificate for Q1 FY27 filed with exchanges · Compliance
- RTA cert filed under SEBI Reg 74(5) for Jun 2026 quarter · Compliance
- Krebs board approves merger with Ipca Labs; share swap 7 Ipca shares per 200 Krebs shares · Strategic Transactions
- Board approves merger with Ipca Laboratories · Strategic Transactions
- Krebs board approves merger with Ipca Labs at 7:200 share swap · Strategic Transactions
- Trading window closure from June 30 ahead of Q1 results · Compliance
- Trading window closure ahead of Q1FY27 results · Compliance
- The Company has enclosed herewith Annual Secretarial Complince Report for the yaer ended 31.03.2026. · Compliance
- Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
- The Company has enclosing herewith copy of newspapers advetiement of financial resulst for the quarter and yaer ended 31.03.2026. · Compliance
- Krebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. · Results
- Audited Results for fiancial yaer ended 31.03.2026 · Results
- Outcome of Board Meeting 21.05.2026 · Results
- Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Pursuant to .... · Board & Shareholder Meetings
- Significant movement in price has been observed in Krebs Biochemicals and Industries Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Krebs Biochemicals and Industries Limited has submitted their response. · Compliance
- Ipca Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. · Ownership Changes
- Avinash Ravi For and on behalf of Dr. R.T. Ravi Mrs. Hemalata Ravi Mr. Avinash Ravi Mr. Aditya Ravi Mr. Ajay Ravi has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. · Ownership Changes
- Significant movement in price has been observed in Krebs Biochemicals and Industries Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. · General
- Krebs Biochemicals and Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 · Compliance
- Krebs Biochemicals and Industries Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 · Compliance
- Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
- Krebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025. · Results
- Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 ,inter alia, to consider and approve Board Meeting .... · Board & Shareholder Meetings
- Krebs Biochemicals and Industries Limited has informed the Exchange regarding ''. · Compliance
- Krebs Biochemicals and Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 · Compliance
- Krebs Biochemicals and Industries Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 · Compliance
- Krebs Biochemicals and Industries Limited has informed the Exchange regarding 'RTA Report on Re-lodgement of transfer requests of physical shares'. · Compliance
- Krebs Biochemicals and Industries Limited has informed the Exchange regarding 'Report on Re-lodgement of transfer requests of physical shares'. · Compliance
- Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
- Krebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025. · Results
- Krebs Biochemicals and Industries Limited has informed the Exchange regarding Board meeting held on November 04, 2025. · Results
- Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2025 ,inter alia, to consider and approve The Company .... · Board & Shareholder Meetings
- Krebs Biochemicals and Industries Limited has informed the Exchange regarding 'Re-lodgement of transfer requests of physical shares'. · Compliance
- Krebs Biochemicals and Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 · Compliance
- Krebs Biochemicals and Industries Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 26, 2025 · Board & Shareholder Meetings
- Krebs Biochemicals and Industries Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 26, 2025 · Board & Shareholder Meetings
- Krebs Biochemicals and Industries Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 · Compliance
- The Company has enclosed herewith RTA Report on re-lodgement of transfer of physical shares upto 31.08.2025. · Compliance
- Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith notice published in the Newspaper (published in Business standard and Prajaskati), issued to the shareholders of the Company with respect to Notice of 33rd Annual General Meeting. · Compliance
- Krebs Biochemicals and Industries Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 26, 2025 · Board & Shareholder Meetings
- Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
- Krebs Biochemicals and Industries Limited has informed the Exchange regarding 'Board comments on fine levied by Exchanges'. · Regulatory & Legal
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹25 Cr over the trailing twelve months.
Market Cap
₹121 Cr
P / E (TTM)
—
EV / EBITDA
—
Div Yield
—
Growth
-15.1%▼
Revenue 5y CAGR
PAT — · EBITDA —
Quality
-19.6%·
ROCE (5y median)
ROE 18.4% · margin -14.4%
Leverage
-1.38·
Debt / Equity · low
Net debt ₹225 Cr
Revenue FY21→FY26
0.4×▼
Margin −18.5 pts
₹54 Cr → ₹24 Cr
Moves on a normal day
1.65%·
Median daily move
Last 268 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
ROCE#173/183
ROE#86/171
Debt / Equity#3/171
EBITDA margin#95/165
Revenue growth#53/161
Profit growth#64/158
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Debt at -1.38× equity
lower than 99% of its 171 Pharmaceuticals peers
Negative working-capital cycle — the business is funded by its suppliers
Concerns
Slow revenue growth — -15% a year over 5 years
Returns on capital -19.6% (5-year median)
#173 of 183 in Pharmaceuticals on the latest reported figures
Charts
How has the market priced it — with filings on the timeline?
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from KREBS BIOCHEMICALS & IND's filed financials and exchange disclosures
What does KREBS BIOCHEMICALS & IND do?
KREBS BIOCHEMICALS & IND is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol KREBSBIO.
Is KREBS BIOCHEMICALS & IND profitable?
No. Over the trailing twelve months KREBS BIOCHEMICALS & IND reported a net loss of ₹14 Cr on revenue of ₹25 Cr.
Does KREBS BIOCHEMICALS & IND pay a dividend?
Not in the latest reported year — KREBS BIOCHEMICALS & IND's dividend payout for FY26 was nil.
Is KREBS BIOCHEMICALS & IND debt-free?
Effectively yes. Debt stands at -1.38× equity.
How much does the KREBS BIOCHEMICALS & IND share price move in a day?
On a typical session KREBS BIOCHEMICALS & IND moves 1.65% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Where can I track KREBS BIOCHEMICALS & IND's announcements?
Every NSE and BSE filing by KREBS BIOCHEMICALS & IND appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.